HCV protease inhibitor telaprevir: Phase II clinical results

Drug Discovery Today

Volumn 15, Issue 9-10, 2010, Pages 406-

  Peese, Kevin ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR;

CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG STRUCTURE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; PHASE 2 CLINICAL TRIAL; SHORT SURVEY;

EID: 77952544197     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.08.009     Document Type: Short Survey

References (2)

1. McHutchison J.G., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N. Engl. J. Med. 2009, 360:1827-1838.
2. McHutchison J.G., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 2009, 360:1839-1850.